New drug cocktail shows promise against tough cancers
NCT ID NCT05214482
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a combination of two experimental drugs, AK112 and AK117, with or without chemotherapy, in 154 people with advanced solid tumors. The goal was to see if the combo could shrink tumors and control the disease. The trial has finished, and researchers are now looking at safety and how well the treatment worked.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AK112 (PD-1/VEGF bispecific antibody) and AK117 (anti-CD47 antibody) with or without chemotherapy
- What this could lead to
- If successful, this combination could offer a new treatment option for people with advanced solid tumors, potentially shrinking tumors and extending life.
- What could go wrong
- This is an early-phase trial (Phase 1/2) with a small number of participants, so results may not apply to everyone. The drugs can cause side effects like immune-related reactions or bleeding risks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, 310000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can pancreatic Cancer's inflammatory footprint be stopped?
- Can sound waves supercharge immunotherapy against bile duct cancer?
- Can AI-Guided home training boost recovery from gastric cancer surgery?
- Can your own immune cells beat advanced cancer?
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?